About: Considerations for people with diabetes during the Coronavirus Disease (COVID-19) Pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Considerations for people with diabetes during the Coronavirus Disease (COVID-19) Pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Considerations for people with diabetes during the Coronavirus Disease (COVID-19) Pandemic
Creator	Mbbs, Ekinci, Elif Fleming, Nicola Neoh, Sandra Pham, Cecilia Sacks, Lori
Source	Elsevier; Medline; PMC
abstract	Abstract Introduction The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) continues to cause havoc globally, resulting in unprecedented healthcare, societal and economic disruption. People with diabetes have been shown to be at higher risk of complications and death when exposed to pneumonia, influenza and other coronaviruses. Despite pandemic scale infection, there is currently limited understanding on the potential impact of SARS-CoV-2 on people with diabetes. Aims (1) To characterise the outcomes of SARS-CoV-2 for people with diabetes and (2) add value to current recommendations for healthcare providers and people with diabetes to encourage optimal management. Methods A search of PubMed, Embase and MEDLINE to March 2020 was undertaken, using search terms pertaining to diabetes, coronavirus and acute respiratory distress syndrome (ARDS). We briefly reviewed the epidemiology and pathophysiology of SARS-CoV in the context of diabetes. Conclusion People with diabetes are at greater risk of severe infection and death with COVID-19. COVID-19 has significantly impacted the daily lives of individuals living with diabetes through financial implications, food and medication scarcity and its burden on mental health. In Australia, delivery of medical care has been adapted to reduce the risk of transmission, with a particular emphasis on telehealth and remote monitoring.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1016/j.diabres.2020.108296
bibo:pmid	32623041
has license	els-covid
sha1sum (hex)	88f6956b2328a6023f28314b86e36d07374b1082
schema:url	https://doi.org/10.1016/j.diabres.2020.108296
resource representing a document's title	Considerations for people with diabetes during the Coronavirus Disease (COVID-19) Pandemic
has PubMed Central identifier	PMC7332442
has PubMed identifier	32623041
schema:publication	Diabetes Res Clin Pract
resource representing a document's body	covid:88f6956b2328a6023f28314b86e36d07374b1082#body_text
is schema:about of	named entity 'ACE2' named entity 'diabetes' named entity 'terms' named entity 'Methods' named entity 'optimal' named entity 'Coronavirus' named entity 'Pandemic' named entity 'EPIDEMIOLOGY' named entity 'HEALTHCARE' named entity 'LIMITED' named entity 'MEDICAL CARE' named entity 'RESULTING IN' named entity 'EMBASE' named entity 'IMPACTED' named entity 'DIABETES' named entity 'ARTICLE' named entity 'Word' named entity 'diabetes' named entity 'COVID-19' named entity 'burden' named entity 'greater' named entity 'epidemiology' named entity 'coronavirus' named entity 'infection' named entity 'care' named entity 'Middle East respiratory syndrome' named entity 'medication' named entity 'healthcare providers' named entity 'daily' named entity 'coronavirus disease 2019' named entity 'higher' named entity 'Journal' named entity 'Coronavirus' named entity 'acute respiratory distress syndrome' named entity 'Middle East respiratory syndrome coronavirus' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'corona virus' named entity 'coronavirus' named entity 'SARS-CoV' named entity 'diabetes' named entity 'people with diabetes' named entity 'add' named entity 'implications' named entity 'Australia' named entity 'nausea' named entity 'angiotensin II' named entity 'nephropathy' named entity 'telehealth' named entity 'health services' named entity 'bactericidal' named entity 'pre-hospital' named entity 'hyperglycaemia' named entity '95% CI' named entity 'MERS-CoV' named entity 'COVID-19 disease' named entity 'type 2 diabetes' named entity 'arterial stiffness' named entity 'adaptive immune response' named entity 'virus' named entity 'ACE2' named entity 'China' named entity 'observational studies' named entity 'quarantine' named entity 'ACE2' named entity 'glycaemic index' named entity 'mmol/l' named entity 'China' named entity 'animal studies' named entity 'nurse educator' named entity 'nurse educator' named entity 'negative feedback loop' named entity 'ARBs' named entity 'diabetes' named entity 'coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software